Γ
Content Highlights || Full Agenda
Breakout Session

4:30 PM

-

5:15 PM

Longevity

Mitochondrial transplantation and genome editing: engineering the metabolic engine of complex life

Mitochondria are often pigeon-holed as the "powerhouse of the cell", giving the false impression that their primary role is as an ATP generator passively responding to the energetic demands of their environment. This is far from the truth. The mitochondria exist as a dynamic network that senses, integrates, and transduces biochemical, energetic, and physical signals, and these signals shape cell fate, lifespan, cancer risk, and more. This session explores emerging tools and methods to edit the small, maternally-inherited, circular mitochondrial genome present in dozens-to-hundreds of copies per cell as a means to prevent mitochondrial disease and optimize metabolic fitness. Additionally, we will discuss the promise of mitochondrial transplantation methodologies as a therapeutic intervention and to discuss the possible routes for mitochondrial metabolic engineering and a range of synthetic developments.

Breakout Session

4:30 PM

-

5:15 PM

Longevity

Mitochondrial transplantation and genome editing: engineering the metabolic engine of complex life

Mitochondria are often pigeon-holed as the "powerhouse of the cell", giving the false impression that their primary role is as an ATP generator passively responding to the energetic demands of their environment. This is far from the truth. The mitochondria exist as a dynamic network that senses, integrates, and transduces biochemical, energetic, and physical signals, and these signals shape cell fate, lifespan, cancer risk, and more. This session explores emerging tools and methods to edit the small, maternally-inherited, circular mitochondrial genome present in dozens-to-hundreds of copies per cell as a means to prevent mitochondrial disease and optimize metabolic fitness. Additionally, we will discuss the promise of mitochondrial transplantation methodologies as a therapeutic intervention and to discuss the possible routes for mitochondrial metabolic engineering and a range of synthetic developments.

SynBioBeta is where the people building with biology meet the people funding, buying, and partnering with them. If you're raising capital, scouting the next wave of AIxBIO companies, or looking for your next technology partner - the people you need are here for three days.

The startups on stage this year are building programmable RNA medicines, virtual cell models, AI-designed enzymes, and proteins that replace sugar - alongside GSK, Sanofi, Novo Nordisk, Eli Lilly, J&J, Mars, Apple, Google, NVIDIA, Unilever, and P&G.

Watching where the partnerships form and which technologies the biggest players are actually evaluating is something you can't get from a report or a webinar. And our 1:1 Partnering App lets you book meetings before you arrive.

“SynBioBeta is a who’s who of AI and biology.
This is where the future is being built, so don't miss it”
“SynBioBeta is a who’s who of AI and biology.
This is where the future is being built, so don't miss it”

Eric Schmidt

Former CEO

"For every single fund at Boom Capital, one of our best companies has come directly from SynBioBeta. I met Mammoth Bio at SynBioBeta, and I met Nabla Bio at SynBioBeta."

Celestine Schnugg

Founder

"Nabla was accelerated into existence because of SynBioBeta. I met Seth Bannon from 50 Years, Cee Cee Schnugg from Boom Capital, and others from Y Combinator there, and those same people seeded Nabla. The vibe, leverage, and energy at SynBioBeta are unreal."
"Nabla was accelerated into existence because of SynBioBeta. I met Seth Bannon from 50 Years, Cee Cee Schnugg from Boom Capital, and others from Y Combinator there, and those same people seeded Nabla. The vibe, leverage, and energy at SynBioBeta are unreal."

Surge Biswas

Founder

"Our Series A came together because of a little bit of SynBioBeta magic. I’ve been attending for a decade and it’s been inspiring to watch the field evolve from a lot of hopes and dreams to real products and applications."
"Our Series A came together because of a little bit of SynBioBeta magic. I’ve been attending for a decade and it’s been inspiring to watch the field evolve from a lot of hopes and dreams to real products and applications."

Jacob Glanville

Founder & CEO

"I met Algen at SynBioBeta and later invested in the company. It’s exactly the kind of connection that makes the community so valuable."
"I met Algen at SynBioBeta and later invested in the company. It’s exactly the kind of connection that makes the community so valuable."

Bill Tai

Co-founder

"At SynBioBeta I met the team at Biomatter, an AI-driven enzyme design company. The environment made it easy to start a real conversation. That conversation turned into a collaboration to improve one of our enzymes. We're now exploring entirely new performance possibilities together."
"At SynBioBeta I met the team at Biomatter, an AI-driven enzyme design company. The environment made it easy to start a real conversation. That conversation turned into a collaboration to improve one of our enzymes. We're now exploring entirely new performance possibilities together."

Luis Cascao-Pereira

Head of Digital Biology

"Every time I attend SynBioBeta, I walk away with something transformative – a new investor, a fantastic hire, or an idea that changes how we work. It’s a community unlike any other."
"Every time I attend SynBioBeta, I walk away with something transformative – a new investor, a fantastic hire, or an idea that changes how we work. It’s a community unlike any other."

Ola Wlodek

CEO

Who’s Coming to SynBioBeta?

And the BD and R&D Leads
That Will Be Your Customers and Partners: